Zhou, Guofa http://orcid.org/0000-0001-9283-5520
Lee, Ming-chieh
Atieli, Harrysone E.
Githure, John I.
Githeko, Andrew K.
Kazura, James W.
Yan, Guiyun
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (3U19AI129326-03S1, U19 AI129326)
Article History
Received: 18 March 2020
Accepted: 2 July 2020
First Online: 20 July 2020
Ethics approval and consent to participate
: Ethical clearance has been obtained from the Ethical Review Committee of Maseno University, Kenya (MSU/DRPI/MUERC/00778/19), and the Institutional Review Board (IRB) of the University of California, Irvine, USA (HS# 2017-3512). Written consent will be obtained from all study participants. Written assent for children (< 18 years of age) will be obtained from the participants and their parents or guardians. Inclusion criteria are as follows: provision of informed consent (assent for children) and no reported chronic or acute illness other than malaria. Exclusion criteria are as follows: unwillingness to participate in the study or reported chronic or acute illness other than malaria. Permission to use microbial larvicides for malaria vector control has been obtained from the Pest Control Products Board of Kenya. All investigative team members in the USA and Kenya have no financial conflict of interest with the larvicide manufacturer, Central Life Sciences.
: Not applicable.
: The authors declare that they have no competing interests.